{"title":"Association between albumin-corrected calcium and all-cause mortality in patients with heart failure: a retrospective study.","authors":"Xiongda Yao, Yurong Leng, Junda Cao","doi":"10.3389/fcvm.2025.1552807","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF), a global health challenge, is a leading cause of mortality in hospitalized patients. Early and accurate prognostic evaluation in these patients is vital for guiding clinical management. Our aim was to explore the association between albumin-corrected calcium (ACC) and mortality in hospitalized patients.</p><p><strong>Methods: </strong>This retrospective cohort study utilized data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Patients were stratified into three groups based on ACC levels. The association between ACC and clinical outcomes in HF patients was analyzed using Cox proportional hazards regression and restricted cubic spline models.</p><p><strong>Results: </strong>A total of 4,737 heart failure patients were included. Multifactorial Cox regression revealed that elevated ACC levels were significantly associated with increased 30-day and 180-day mortality. Restricted cubic spline analysis demonstrated a U-shaped relationship between ACC levels and mortality, with an inflection point at 9.18. Patients with ACC levels above 9.18 exhibited an 20.4% higher risk of 30-day mortality [Hazard ratio (HR): 1.204, 95% (Confidence interval) CI: 1.009-1.437] and a 20.8% higher risk of 180-day mortality (HR: 1.208, 95% CI: 1.019-1.431) compared to those with ACC below 9.18.</p><p><strong>Conclusions: </strong>The observed U-shaped association between ACC levels and 30- and 180-day mortality in HF patients highlights the potential utility of ACC as a prognostic marker.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1552807"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1552807","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Heart failure (HF), a global health challenge, is a leading cause of mortality in hospitalized patients. Early and accurate prognostic evaluation in these patients is vital for guiding clinical management. Our aim was to explore the association between albumin-corrected calcium (ACC) and mortality in hospitalized patients.
Methods: This retrospective cohort study utilized data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Patients were stratified into three groups based on ACC levels. The association between ACC and clinical outcomes in HF patients was analyzed using Cox proportional hazards regression and restricted cubic spline models.
Results: A total of 4,737 heart failure patients were included. Multifactorial Cox regression revealed that elevated ACC levels were significantly associated with increased 30-day and 180-day mortality. Restricted cubic spline analysis demonstrated a U-shaped relationship between ACC levels and mortality, with an inflection point at 9.18. Patients with ACC levels above 9.18 exhibited an 20.4% higher risk of 30-day mortality [Hazard ratio (HR): 1.204, 95% (Confidence interval) CI: 1.009-1.437] and a 20.8% higher risk of 180-day mortality (HR: 1.208, 95% CI: 1.019-1.431) compared to those with ACC below 9.18.
Conclusions: The observed U-shaped association between ACC levels and 30- and 180-day mortality in HF patients highlights the potential utility of ACC as a prognostic marker.
Jocelyn L K Tan, Anna-Mari Ylä-Kojola, Johan G Eriksson, Minna K Salonen, Niko Wasenius, Nicolas H Hart, Paola Chivers, Timo Rantalainen, Aulikki Lano, Harri Piitulainen
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.